Leash Biosciences secures $9.3 million in seed funding to revolutionize medicinal chemistry using AI. Stanford Medicine researchers develop GenerativeAI for creating new drugs. AI is increasingly prominent in drug development, lowering costs and resources. Empress_Tx utilizes AI to create small molecule medicines by decoding DNA programs.
#BiggerLeaps in science are often achieved by learning from Nature’s experiments. We use #AI to generate new #smallmolecule medicines by decoding eon’s worth of chemistry written into DNA programs. Learn more from @GrinsteinJ’s @GENbio article: https://t.co/S1CJCnFSfZ
#AI for drug discovery, computational biology, and life sciences are costly and computationally intensive to run. #SkyNet pushes the envelope by lowering the barrier to entry, and decreasing required resources and upfront overhead cost to near zero. Previously Google Cloud’s… https://t.co/zwexyvUqGD
Artificial intelligence is taking over drug development, per the Economist.
#GenerativeAI develops potential new drugs for antibiotic-resistant bacteria @StanfordMedicine researchers devise a new AI model, SyntheMol, which creates recipes for chemists to synthesize the drugs in the lab. https://t.co/1KOpOR4pWb #pharma
Leash Biosciences: Transforming Medicinal Chemistry with AI and $9.3 Million Seed Funding #AI #AIdriven #artificialintelligence #Biotechnology #drugdiscovery #Investment #Kagglecompetition #LeashBiosciences #llm #machinelearning #medicinalchemistry https://t.co/s88wabzEKv https://t.co/xz8HUSUxUt